Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases.
The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu (brolucizumab) to treat patients with diabetic macular edema (DME).
Poseida Therapeutics has signed a research collaboration and license agreement with Takeda Pharmaceutical Company to develop up to eight in vivo gene therapy programmes.
Pacira BioSciences has signed a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to strengthen its position in non-opioid pain management.
The US Food and Drug Administration (FDA) has accepted the filing of a new drug application (NDA) for Acer Therapeutics and Relief Therapeutics’ ACER-001 (sodium phenylbutyrate) to treat people with urea cycle disorders (UCDs).
AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m.
Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir).
UNION therapeutics has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China.
Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.
AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.